Design and rationale of a multi-center, pragmatic, open-label randomized trial of antimicrobial therapy – the study of clinical efficacy of antimicrobial therapy strategy using pragmatic design in Idiopathic Pulmonary Fibrosis (CleanUP-IPF) clinical trial

MLA

Kevin J. Anstrom, et al. “Design and Rationale of a Multi-Center, Pragmatic, Open-Label Randomized Trial of Antimicrobial Therapy – the Study of Clinical Efficacy of Antimicrobial Therapy Strategy Using Pragmatic Design in Idiopathic Pulmonary Fibrosis (CleanUP-IPF) Clinical Trial.” Respiratory Research, vol. 21, no. 1, Mar. 2020, pp. 1–13. EBSCOhost, https://doi.org/10.1186/s12931-020-1326-1.

APA

Kevin J. Anstrom, Imre Noth, Kevin R. Flaherty, Rex H. Edwards, Joan Albright, Amanda Baucom, Maria Brooks, Allan B. Clark, Emily S. Clausen, Michael T. Durheim, Dong-Yun Kim, Jerry Kirchner, Justin M. Oldham, Laurie D. Snyder, Andrew M. Wilson, Stephen R. Wisniewski, Eric Yow, Fernando J. Martinez, & For the CleanUP-IPF Study Team. (2020). Design and rationale of a multi-center, pragmatic, open-label randomized trial of antimicrobial therapy – the study of clinical efficacy of antimicrobial therapy strategy using pragmatic design in Idiopathic Pulmonary Fibrosis (CleanUP-IPF) clinical trial. Respiratory Research, 21(1), 1–13. https://doi.org/10.1186/s12931-020-1326-1

Chicago

Kevin J. Anstrom, Imre Noth, Kevin R. Flaherty, Rex H. Edwards, Joan Albright, Amanda Baucom, Maria Brooks, et al. 2020. “Design and Rationale of a Multi-Center, Pragmatic, Open-Label Randomized Trial of Antimicrobial Therapy – the Study of Clinical Efficacy of Antimicrobial Therapy Strategy Using Pragmatic Design in Idiopathic Pulmonary Fibrosis (CleanUP-IPF) Clinical Trial.” Respiratory Research 21 (1): 1–13. doi:10.1186/s12931-020-1326-1.